AUSTRIA and Germany will become the first markets in the European Union to launch Alzhemier’s drug Leqembi (lecanemab, Eisai).

The TGA knocked back Eisai’s application to register the anti-amyloid monoclonal antibody in Australia (PD 04 Mar), citing safety and efficacy concerns.

The post Leqembi in EU appeared first on Pharmacy Daily.